Genetically modified t cells take on glioblastoma

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Procurement Inclusion Criteria: * Diagnosis of GPC3-positive recurrent glioblastoma with previous resection planned for repeat resection. * Age ≥18 years * Karnofsky score ≥60% * Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent * GPC3 expression (as determined by immunohistochemistry) with an extent score of ≥ Grade 2 (\>25% positive tumor cells) and an intensity score of ≥ 2 (scale 0-4). Procurement Exclusion Criteria: * History of hypersensitivity reactions to murine protein-containing products OR presence of human anti-mouse antibody (HAMA) prior to enrollment (only patients who have received prior therapy with murine antibodies). * History of organ transplantation * Known HIV positivity * Active bacterial, fungal or viral infection (except Hepatitis B or Hepatitis C virus infections). * Exhibits other risk factors of which administration of investigational agent is deemed not in the patient's best interest, in the opinion of the investigator Treatment Inclusion Criteria: * Age ≥ 18 years * Diagnosis of recurrent glioblastoma with previous resection * Karnofsky score ≥ 60%- * Stable neurologic exam for 7 days prior to enrollment * Stable or decreasing dose of steroids over past 7 days prior to surgery and administration of therapy (max allowable dose is 0.1mg/kg dexamethasone or equivalent per day) * Adequate organ function: * Creatinine clearance as estimated by Cockcroft Gault or Schwartz ≥ 60 ml/min * total bilirubin \< 3 times ULN for age * INR ≤1.7 * absolute neutrophil count \> 500/μl * platelet count \> 100,000/μl (can be transfused but must be achieved prior to enrollment) * Hgb ≥ 7.0 g/dl (can be transfused) * Pulse oximetry \>90% on room air * Recovered from acute toxic effects of all prior chemotherapy and investigational agents before entering this study * Sexually active patients must be willing to utilize one of the more effective birth control methods for 3 months after the T-cell infusion. * Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent. Treatment Exclusion Criteria: * Pregnancy or lactation * Uncontrolled infection * Known HIV positivity * Active bacterial, fungal or viral infection * History of organ transplantation * History of hypersensitivity reactions to murine protein-containing products OR presence of human anti-mouse antibody (HAMA) prior to enrollment (only patients who have received prior therapy with murine antibodies)